ArticleAntibiotics (Basel, Switzerland)2025
Report of High-Risk Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Comparison of microbial profiles between hospital wastewater and river water.Molecular genetics and genomics : MGG · 2026Article
- Pandemic SHV-106-producing Klebsiella pneumoniae ST231 isolated from Brazilian hedgehog (Coendou spinosus) reveals an emerging environmental circulation of a high-risk multidrug-resistant lineage.Antonie van Leeuwenhoek · 2026Article
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Sustainable thymol-based formulations with amoxicillin andFrontiers in chemistry · 2026Article
- Urinary Tract Infections in a Single-Center Bulgarian Hospital: Trends in Etiology, Antibiotic Resistance, and the Impact of the COVID-19 Pandemic (2017-2022).Antibiotics (Basel, Switzerland) · 2025Article
- Epidemiological and Microbiological Characterization of Carbapenemase-ProducingMicroorganisms · 2025Article
- Genomic Characterization of Multidrug-Resistant and ESBL-ProducingMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectives
methodsIn this study, a carbapenem-resistant
resultsA genomic analysis also revealed the presence of virulence factors such as
conclusionsThe coexistence of these resistance genes in addition to aminoglycoside, quinolone, and other resistance genes results in difficult-to-treat infections caused by respective carrier strains, often requiring the use of last-resort antibiotics and contributing to the global challenge of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.